Ganciclovir Therapeutic Drug Monitoring in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy
The Journal of Pediatric Pharmacology and Therapeutics · 2026-06 · 31 (3) · 366-371
DOI: 10.5863/jppt-25-00042 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pediatric Pharmacology and Therapeutics, 2026-06. Verfasst von Christina J Smith und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy (CJS, LJW, KR, SVK), Seattle Children's Hospital, Seattle, WA. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVE Ideal ganciclovir dosing for the treatment of cytomegalovirus and herpesvirus in children receiving continuous renal replacement therapy (CRRT) is unknown. Available literature regarding ganciclovir pharmacokinetics (PK) in children suggests high interpatient variability and risk of underexposure. Therapeutic drug monitoring (TDM) may be of benefit in pediatric patients to optimize dosing, with a 24-hour area under the curve (AUC 24 ) of 80 to 120 mg·hr/L proposed as the treatment target. Even with TDM, limited data exist to guide dosing in critically ill children requiring CRRT. The goal of this study was to evaluate ganciclovir dosing and PK in critically ill pediatric patients on CRRT. METHODS This retrospective, single-center cohort study reviewed the electronic medical records of patients 17 years of age or younger who received ganciclovir treatment along with drug concentration monitoring in the pediatric intensive care unit (PICU) between July 2022 and July 2023. Data included ganciclovir dose, PK parameters, CRRT modality, as well as effectiveness and safety outcomes. RESULTS A total of 5 patients (median age, 12 years; IQR, 8.5–14.5) received ganciclovir in the PICU. Patients received continuous venovenous hemodiafiltration at a median clearance rate of 1928 mL/1.73m 2 /hr (IQR, 1860–2162). A ganciclovir dose of 2.5 mg/kg every 12 hours most frequently resulted in a goal AUC 24 of 80 to 120 mg·hr/L. CONCLUSION The results of this study show variable ganciclovir drug exposure in critically ill pediatric patients receiving CRRT. Further study is needed to determine appropriate ganciclovir dosing and the role of TDM in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy (CJS, LJW, KR, SVK), Seattle Children's Hospital, Seattle, WA.
Zitieren
APA
Smith, C. J., Walsh, L. J., Roberts, K. R., & Karwande, S. (2026). Ganciclovir Therapeutic Drug Monitoring in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy. The Journal of Pediatric Pharmacology and Therapeutics, 31(3), 366-371. https://doi.org/10.5863/jppt-25-00042
Vancouver
Smith CJ, Walsh LJ, Roberts KR, Karwande S. Ganciclovir Therapeutic Drug Monitoring in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy. The Journal of Pediatric Pharmacology and Therapeutics. 2026;31(3):366-371. doi:10.5863/jppt-25-00042
BibTeX
@article{Smith2026,
author = {Smith, Christina J and Walsh, Laura J and Roberts, Kyle R and Karwande, Sai},
title = {Ganciclovir Therapeutic Drug Monitoring in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy},
journal = {The Journal of Pediatric Pharmacology and Therapeutics},
year = {2026},
volume = {31},
number = {3},
pages = {366--371},
doi = {10.5863/jppt-25-00042}
}
EUVIMED